Ixico joins forces with Alzheimer's disease neuroimaging initiative

ADNI is a longitudinal multicentre study looking to develop clinical, imaging and biochemical biomarkers for the early detection and tracking of the chronic neurodegenerative disease


Ixico PLC (LON:IXI) said it is providing funding and expertise for the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Two of the neuroscience analytics company's scientists will join the private partner scientific board of ADNI, which is a longitudinal multicentre study looking to develop clinical, imaging, genetic and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.

READ: IXICO gains as it achieves first year of profitability since AIM listing

ADNI aims to achieve its goals through the application of new diagnostic methods in a “pre-competitive environment” and through its partners sharing data to advance the field.

The private partner scientific board is designed to facilitate "open dialogue" around any progress made within the ADNI project and around new trends with Alzheimer's disease-related research and development.

AIM-listed Ixico specialises in data analytics services that identify and measure unique biomarkers from brain scan and wearable biosensor data produced in clinical research programmes.

Ixico chief executive Giulio Cerroni said: “We are proud to support the ADNI initiative which has made a major contribution to setting the imaging standards in AD research and provides access to important clinical data sets to the global research community.

“ADNI's purpose is well-aligned with our own goal to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare which will contribute to the advancement of AD research.

“We look forward to engaging with all members of the consortium to contribute to the success of this initiative.”

Quick facts: IXICO PLC

Price: 65 GBX

Market: AIM
Market Cap: £30.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...



IXICO PLC - Proactive One2One Virtual Event

IXICO PLC's Giulio Cerroni speaks to investors at the Proactive One2One Virtual Event. IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

4 weeks ago

2 min read